StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd (TEVA) stock

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.57−1.93 (-4.34%)

Close on Nov 16, 2026Market cap $49.61BP/E 71.0Yield –

Teva Pharmaceutical Industries pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Teva Pharmaceutical Industries's pe ratio was 70.7× on Nov 10, 2026, against 44.8× a year earlier. Over the last 5 years it ranged from 12.1× to 77.1×, with a median of 27.9×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 10, 202670.7×+18.6
2025Dec 31, 202552.0×+29.1
2022Apr 29, 202222.9×+10.8
2021Dec 31, 202112.1×−7.3
2017Jan 31, 201719.4×−1.6
2016Dec 30, 201621.1×−10.6
2015Dec 31, 201531.7×+13.8
2014Dec 31, 201417.9×−10.3
2013Dec 31, 201328.2×+12.9
2012Dec 31, 201215.3×+3.3
2011Dec 30, 201112.0×−4.1
2010Dec 31, 201016.1×−42.4
2009Dec 31, 200958.5×–

More Teva Pharmaceutical Industries figures

See a number that looks wrong?